AliveCor has been in the news recently for its efforts to support front line personnel during the COVID-19 crisis. Since receiving FDA clearance for its KardiaMobile 6L personal ECG within the last year, the company must be thinking about what's next.
If its IP portfolio is any indication, it is that the future is bright for AliveCor, because it continues to expand and includes dozens of applications. Their most recent application likely seeks to expand the capabilities of the KardiaMobile 6L, and teaches systems, methods, devices, software, and platforms for continuously monitoring a user's low-fidelity health-indicator data from a user-device.
This week, AliveCor announced a new collaboration with the Clifford Lab at Emory University School of Medicine, and the Georgia Institute of Technology. The collaboration seeks to develop new cardiovascular insights using deep learning. The Clifford Lab is focused on reducing costs and improving accuracy and access in healthcare, and has developed applications for mobile and wearable devices that utilize predictive algorithms.
